Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.

Biotechnology

Abcuro

Alex Martin

Stephanie Amador

Eileen Brennan

Weilee Chen

Zarna Patel

Andrew Marth

Jeff Geary

Jeffrey Luk

Karma Tashi

Chidi Obi

Bill Yates

Daniel Mansuri

Kristin Lurk

Ricky Motschwiller

Raquel Orozco

Donna Byrne

Terry Chaney

Mike Gress

Karen Tubridy

Garry Weems

Hugo Lemessurier

Dave Borbas

Janaki Subramanyam

Dulce Soler-Ferran

LaDonna Hoffer

H. Jeffrey Wilkins, MD

Management and Directors

Leadership Team

Quality and Regulatory Team

Supply Chain and Manufacturing

Clinical Operations Team

Finance and Accounting Team

Observers

Data and Technology Team

Teams at Abcuro